The BCL-2 anti-apoptotic proteins are over-expressed in many cancers and hence are attractive therapeutic targets. In this study we tested the sensitivity of two NPC cell lines HK1 and C666-1 to Maritoclax which is reported to repress anti-apoptotic protein MCL-1 and BH3 mimetic ABT-263 which selectively inhibits anti-apoptotic proteins BCL-2, BCL-XL and BCL-w. We investigated the sensitization of the NPC cell lines to these drugs using the SYBR Green I assay and 3D NPC spheroids.
Introduction
NPC is the sixth most common cancer in Southeast Asia (SEA) with Malaysia reporting one of the highest national incidences in SEA [1] . Treating patients with metastatic NPC is often a challenge as patients develop resistance to systemic anti-cancer therapies such as chemotherapy and retreating local recurrence with radiotherapy have many limitations. Thus, novel or improved treatment strategies are urgently needed to curb this disease.
The BCL-2 family proteins are critical regulators of the intrinsic apoptosis pathway [2] .
The anti-apoptotic BCL-2 proteins are reported to be overexpressed in many cancers and thus are attractive therapeutic targets. Utilizing the immunohistochemistry (IHC) technique, BCL-2 expression was detected in 80% NPC tissues and 71% adjacent dysplastic lesions compared to normal nasopharynx epithelia [3] . Employing the same technique, similar results were obtained in other studies [4] [5] [6] . NPC tissues which were positive for BCL-2 expression, highly correlated with neck lymph nodes metastasis [4] and a worse disease-free 5-year survival [7] .
Collectively, these studies suggest that the BCL-2 anti-apoptotic proteins are relevant targets for NPC treatment.
In the present study, we investigated the sensitivity of two NPC cell lines HK1 and C666-1 to single agent treatment of Maritoclax and ABT-263 alone and in combination using 2-dimensional (2D) and 3-dimensional (3D) cell culture models. ABT-263 binds with high affinity to BCL-2 and BCL-XL [8] whereas Maritoclax was reported to antagonize MCL-1 and target the protein for proteasome-mediated degradation [9] .
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Methods
Cells and Cell culture
The human NPC cell lines HK1 and C666-1 were grown and authenticated using the AmpFISTR profiling as described [10] . Cells were not passaged unnecessarily and experiments were performed within 2-3 passages of the foundation stocks.
Western blot analysis
Cells were lysed and analyzed on reducing SDS-PAGE as described [11] . Membranes were blocked with 5% blotto and probed with antibodies against: MCL-1 (clone 22, BD Pharmingen, 
SYBR Green I assay and Synergy analysis
The SYBR Green I assay was conducted as described [12, 13] . The HK1 cells were seeded at a density of 2500 cell/well and the C666-1 cells were seeded at a density of 4000 cells/well in 96-well plates and left to attach for 6-7 hours. Cells were treated to a concentration series [0-32 µM] of single agent Maritoclax (ChemScene, USA) and ABT-263 (Selleckchem, USA) and as combination along the long plate axis for 72 hours. Sensitization to ABT-263 by Maritoclax was assessed by testing a fixed concentration of Maritoclax to increasing concentrations and ABT-263 for 72 hours. Cell proliferation was quantified as described [14] . Synergy studies were conducted by calculating the combination index (CI) using the CalcuSyn 2.11 software (Biosoft Inc, Cambridge, UK). A CI of <1 indicates synergistic effect, CI =1 an additive effect, and CI > 1 antagonism.
Generation of 3D spheroids
Approximately 5000 (2.5 x 10 4 / ml) HK1 cells were seeded in the ultra-low attachment (ULA)
96-well U bottom plate (Corning, USA) and centrifuged at 1200 rpm for 2 minutes. The plates were incubated in a humidified incubator at 37°C with 5% CO₂ for three days. Spheroids were embedded in collagen matrix as described [15, 16] . Spheroids were treated with ABT-263 and
Maritoclax at doses and times required in 1 ml of complete medium and were incubated in a humidified incubator at 37°C with 5% CO₂. Phase contrast snapshots of spheroids were taken every 24 hours using the IX71 Olympus inverted fluorescence microscope over 10 days to document spheroid growth and invasion. Spheroids were washed 3 times in PBS and stained with 4 mmol/L calcein AM and 2 mmol/L ethidium homodimer I (Thermo Fisher Scientific, USA) for an hour at 37°C. Images of spheroids were captured using the IX71 Olympus inverted microscope.
Results
Maritoclax suppresses BCL-2 anti-apoptotic proteins in a dose-and time-dependent manner
The basal expression levels of the anti-apoptotic proteins MCL-1, BCL-XL and BCL-2 in the NPC cells were first investigated. MCL-1 was expressed in both HK1 and C666-1 cells (Fig. 1a ). Higher expression of BCL-2 was found in the C666-1 cells, whereas relatively higher expression of BCL-XL was found in the HK1 cells (Fig. 1a) . (Fig. 1b, c) .
Interestingly, in the C666-1 cells, increasing concentrations of Maritoclax exhibited a transient dose effect on the level of BCL-2 (Fig. 1d) . The reduction of BCL-2 was near complete at 2 µM of Maritoclax but at 4 µM the protein level was restored (Fig. 1d) . However, Maritoclax exhibited a strong time-effect on the level of BCL-2 in the C666-1 cells (Fig. 1e) . The ability of Maritoclax to repress the other anti-apoptotic proteins indicates that it is not a selective MCL-1 inhibitor.
NPC cells sensitive to single agent treatment of Maritoclax in a dose-dependant manner
The sensitivity of the HK1 and C666-1 cells were first tested to single agent Maritoclax (Fig. 3a) . Given that the IC50 concentration of single agent Maritoclax on C666-1 cells was < 1 µM, combination with ABT-263 was not tested.
The spheroids generated from the HK1 cells were also sensitized to ABT-263 by
Maritoclax. The spheroids were treated with ABT-263 and Maritoclax, either alone or in combination over 10 days with medium and drugs replenishment every 72 hours. In the presence of 1 µM Maritoclax, there was obvious sensitization to ABT-263 reflected in dosedependent inhibition of invasion. This also manifested as reduced cell viability (decreased Calcein AM staining and increased Ethidium homodimer I staining) (Fig. 3b) .
Discussion
Given that Maritoclax promoted proteasomal degradation of MCL-1 [9, 17] , there was a reason to believe that combination with ABT-263 may overcome resistance and sensitize the NPC cells to ABT-263. Interestingly, a number of studies reported that Maritoclax did not display a stringent selective cytotoxicity on MCL-1 dependent cell lines [18, 19] . Human leukemia cell line RS4;11 which is dependent on BCL-2 for survival was more sensitive to
Maritoclax treatment compared to HeLa cells which are dependent on MCL-1 for survival.
Furthermore Maritoclax treatment did not alter the expression of MCL-1 in both these lines [18] . In another study, Maritoclax was shown to repress MCL-1 but this effect was not long lasting as the level of MCL-1 was restored at later time points in the MCL-1 dependent H460 cells. However, the drug did not repress the levels of anti-apoptotic proteins BCL-2, BCL-XL and BCL-w in the H460 cells. In contrast, Dinaciclib a broad spectrum CDK inhibitor which was reported to down-regulate MCL-1 exhibited a lasting time effect on the level of MCL-1 in the H460 cells [19] . The same study reported that the treatment with Maritoclax led to more death of the MCL-1 deficient MEFs compared to wild-type MEFs indicating that apoptosis can be triggered via other mechanisms [19] . fold, respectively [9] . Similarly, two acute myeloid cells (AML) namely HL60 and KG1a, which were resistant to ABT-737 due to prolonged culture with the drug, were sensitized to ABT-737 after combination with sub-lethal dose of 2 or 1 µM Maritoclax, respectively [17] .
In our study we had to be more cautious with the concentrations of Maritoclax used when 
